<DOC>
	<DOCNO>NCT02084602</DOCNO>
	<brief_summary>There grow evidence emergence P. falciparum resistance artesunate ( derivative artemisin ) Southeast Asia . The emergence spread resistant strain artemisinin would represent alarm threat success antimalarial combination therapy region . The delayed clearance parasitemia 24 hour take early sign resistance , phenomenon see Thai-Cambodia border . The purpose research study , assess vitro vivo efficacy combinated artesunate/mefloquine therapy treatment uncomplicated Plasmodium falciparum malaria Peruvian Amazon analysis rate clearance parasitemia important outcome .</brief_summary>
	<brief_title>Assessment Artesunate/Mefloquine Peruvian Amazon</brief_title>
	<detailed_description>Combination therapy artemisinin derivative treatment choice malaria P. falciparum since 2006 , grow evidence emergence P. falciparum resistance artesunate Southeast Asia . The delayed clearance parasitemia 24 hour take early sign resistance , phenomenon see Thai-Cambodia border . The emergence spread resistant strain artemisinin would represent alarm threat success antimalarial combination therapy region . This research study , conduct collaboration National Institute Health Peru . Objectives : Main Objective : To determine rate clearance parasitemia first 72 hour administration artesunate . Secondary/exploratory objective : 1. determine efficacy artesunate ( AS ) /mefloquine ( MQ ) therapy participant uncomplicated falciparum malaria Peruvian Amazon ( sub-study ) ; 2. correlate clinical result vivo study result vitro sensitivity molecular genotyping ; 3. identify common specific genetic determinant resistance artemisinins parasite population ; 4. determine level gametocytes participant uncomplicated falciparum malaria treat AS/MQ ; 5. determine contribution host immunity clinical parasitological response ; 6. create catalog parasite sample closely correlate clinical response data perform longitudinal follow-up resistance trend ; 7. determine pharmacokinetic parameter associated failure therapy . Methodology : The study conduct seven health facility one hospital Department Loreto Peruvian Amazon , 59 volunteer enrol 5 65 year age confirm diagnosis monoinfection P. falciparum . In addition main study , conduct sub-study determine efficacy AS/MQ ( regime currently use Peru ) After sign informed consent/assent , blood sample take determine parasite density , baseline biochemical test , genotyping study , analysis molecular marker vitro sensitivity , antibody malaria cytokine . Artesunate administer accord national guideline first three day , 4 mg/kg/day . However , mefloquine administration delay 72 hour measure rate clearance parasitemia artesunate alone first three day . Serial blood sample thick/thin smear take every 4 hour first 12 hour every 6 hour complete first 72 hour , AS administration , time study participant remain hospital ward . Monitoring undertaken day 42 analysis thick/thin smear accord WHO guideline . In case parasitemia recurrence , additional blood sample collect genotyping test , vitro sensitivity , analysis molecular marker drug resistance immunology assay . The sub-study useful ass efficacy regimen currently use Ministry Health Peru , arm patient give AS 4 mg/kg/day Days 0 , 1 2 MQ 12.5mg/kg/day Days 1 2 . In arm , follow do use thick smear Days 1 , 2 , 3 , 7 , 14 , 21 , 28 , 35 42 . Blood sample collect Days 0 , 42 day recurrence . This study allow Ministry Health know state resistance/tolerance artesunate Peru take necessary control measure ensure artesunate use successfully treatment falciparum malaria . Importantly , result study compare parallelly-designed study Kenya ( US Army Medical Research Unit Kenya-USAMRU K ) Thailand ( Army Forces Medical Research Institute Medical Sciences-AFRIMS ) . Relevance : Malaria one main public health problem Peru , early efficacious treatment principal control strategy appearance strain resistant regular treatment use Peru jeopardize strategy malaria control South America . This study allow u know current resistance status prepare correspond measure . Budget : This study do join effort NAMRU-6 INS , cost 201,934.93 Nuevos Soles afford Instituto Nacional de Salud total cost 527,934.93 Nuevos Soles participate institution</detailed_description>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Mefloquine</mesh_term>
	<criteria>Age 5 65 year old inclusive Monoinfection P. falciparum confirm microscopy Documented fever ( axillary temperature &gt; 37.5°C ) and/or history fever previous 48 hour absence obvious cause fever ( pneumonia , otitis medium , etc ) Infection P. falciparum 1000 100,000 asexual parasite per microliter ( μl ) determine microscopic examination thick thin smear , positive confirmation polymerase chain reaction ( PCR ) ; * Presence sexual form P. vivax acceptable ; ** PCR confirmation enrollment requirement Informed consent must obtain participant parents/guardian ( case child ) , assent child ( 8 17 year old ) Willingness participant return health facility regular checkup followup period 42 day Willingness participant transfer Hospital de Apoyo Iquitos start treatment Severe malaria sign ( define World Health Organization ) : 1 . Cerebral malaria ( irreversible coma ) 2 . Severe anemia ( hematocrit &lt; 15 % , clinic sign ) 3 . Clinic sign kidney failure ( e.g. , serum creatinine &gt; 3 mg/dL ) 4 . Pulmonary edema 5 . Hypoglycemia ( glucose blood &lt; 40mg/dL clinic sign ) 6 . Shock ( PA systolic &lt; 70 mm Hg adult ; &lt; 50 child ) 7 . Spontaneous bleeding/Disseminated intravascular coagulation ( CID ) 8 . Recurrent generalize convulsion 9 . Acidemia/acidosis ( clinic sign ) 10 . Macroscopic hemoglobinuria 11 . Jaundice Laboratory test measure condition may available study site . If , use clinical criterion severe malaria discretion study physician Background chronic severe disease ( e.g. , heart , kidney , liver disease , HIV/AIDS , severe malnutrition ) , determine clinically medical history physical examination Background hypersensitivity drug test used alternative treatment : AS , MQ , quinine tetracycline/clindamycin Gestation ( base serum pregnancy test medical history ) desire become pregnant study period , use family planning method sexually active ( confirmed urine pregnancy test ) Breastfeeding child 6 month old Have receive antimalarial drug previous 7 day Inability eat drink , vomit ( twice last 24 hour ) , recent history seizure ( one previous 24 hour ) , alter level consciousness , inability sit stand Splenectomy background</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>artesunate</keyword>
	<keyword>mefloquine</keyword>
	<keyword>falciparum</keyword>
	<keyword>peruvian amazon</keyword>
</DOC>